Distinguishing features of endometrial pathology after exposure to the progesterone receptor modulator mifepristone

被引:43
作者
Fiscella, Julietta [2 ]
Bonfiglio, Thomas [2 ]
Winters, Paul [1 ]
Eisinger, Steven H. [1 ,3 ]
Fiscella, Kevin [1 ]
机构
[1] Univ Rochester, Sch Med, Sch Med & Dent, Dept Family Med, Rochester, NY 14620 USA
[2] Univ Rochester, Sch Med, Sch Med & Dent, Dept Pathol, Rochester, NY 14620 USA
[3] Univ Rochester, Sch Med, Sch Med & Dent, Dept Obstet, Rochester, NY 14620 USA
关键词
Endometrium/pathology; Endometrium/drug effects; Leiomyoma; Mifepristone; LOW-DOSE MIFEPRISTONE; RANDOMIZED CONTROLLED-TRIAL; UTERINE LEIOMYOMATA; DOUBLE-BLIND; ESTROGEN; ASOPRISNIL; WOMEN;
D O I
10.1016/j.humpath.2010.11.003
中图分类号
R36 [病理学];
学科分类号
100103 [病原生物学];
摘要
There is growing interest in the use of progesterone receptor modulators such as mifepristone for treatment of gynecologic and other conditions, but interest in progesterone receptor modulators is dampened by the effects of the agents on the endometrium. In this study, we examined the endometria of women exposed to mifepristone for treatment of leiomyomas in doses of 2.5 and 5 mg and compared them to unexposed endometria. We assessed the reliability of these features by comparing agreement in ratings between pathologists who were blinded to each other's readings. We assessed distinguishing features between exposed and unexposed groups by comparing frequency of features between groups. We found that key features could be reliably assessed by pathologists experienced in endometrial pathology. We observed several features (nonsynchronous endometrium, large fluid filled glands, and abnormal blood vessels) that distinguished endometrial samples that were and were not exposed to the drug. These findings suggest several features that can be tracked during studies involving mifepristone and, potentially, other progesterone receptor modulators. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:947 / 953
页数:7
相关论文
共 23 条
[1]
Low-dose mifepristone in treatment of uterine leiomyoma: A randomised double-blind placebo-controlled clinical trial [J].
Bagaria, Madhu ;
Suneja, Amita ;
Vaid, Neelam B. ;
Guleria, Kiran ;
Mishra, Kiran .
AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY, 2009, 49 (01) :77-83
[2]
Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: A double-blind randomized control trial of 2 and 5 mg per day for 120 days [J].
Brown, A ;
Cheng, LN ;
Lin, SQ ;
Baird, DT .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (01) :63-70
[3]
Esteve JLC, 2008, OBSTET GYNECOL, V112, P1029, DOI 10.1097/AOG.0b013e31818aa930
[4]
Effects of long-term low-dose mifepristone on reproductive function in women [J].
Croxatto, HB ;
Kovács, L ;
Massai, R ;
Resch, BA ;
Fuentealba, B ;
Salvatierra, AM ;
Croxatto, HD ;
Zalányi, S ;
Viski, S ;
Krenacs, L .
HUMAN REPRODUCTION, 1998, 13 (04) :793-798
[5]
Low-dose mifepristone for uterine leiomyomata [J].
Eisinger, SH ;
Meldrum, S ;
Fiscella, K ;
le Roux, HD ;
Guzick, DS .
OBSTETRICS AND GYNECOLOGY, 2003, 101 (02) :243-250
[6]
EISINGER SH, 2009, EUR J OBSTE IN PRESS
[7]
Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial [J].
Engman, M. ;
Granberg, S. ;
Williams, A. R. W. ;
Meng, C. X. ;
Lalitkumar, P. G. L. ;
Gemzell-Danielsson, K. .
HUMAN REPRODUCTION, 2009, 24 (08) :1870-1879
[8]
Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size - A randomized controlled trial [J].
Fiscella, Kevin ;
Eisinger, Steven H. ;
Meldrum, Sean ;
Feng, Changyong ;
Fisher, Susan G. ;
Guzick, David S. .
OBSTETRICS AND GYNECOLOGY, 2006, 108 (06) :1381-1387
[9]
Progesterone, but not estrogen, stimulates vessel maturation in the mouse endometrium [J].
Girling, Jane E. ;
Lederman, Fiona L. ;
Walter, Lisa M. ;
Rogers, Peter A. W. .
ENDOCRINOLOGY, 2007, 148 (11) :5433-5441
[10]
REGRESSION MODELING STRATEGIES FOR IMPROVED PROGNOSTIC PREDICTION [J].
HARRELL, FE ;
LEE, KL ;
CALIFF, RM ;
PRYOR, DB ;
ROSATI, RA .
STATISTICS IN MEDICINE, 1984, 3 (02) :143-152